Navigation Links
Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
Date:10/15/2007

of the call will be available until 9:29 p.m. on October 22, 2007.

This press release contains forward-looking statements, including statements about timelines for obtaining and presenting clinical trial data, the expected efficacy of alemtuzumab in MS and its comparison to current market products, the possibility of approval of alemtuzumab in MS, and the continued enrollment of patients in related MS clinical trials. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others, that actual results of the clinical trials demonstrate safety and efficacy comparable to the data that have emerged to date, the actual timing and content of submissions to and decisions made by the regulatory authorities, institutional review boards, data safety monitoring boards and treating physicians regarding the continued administration of alemtuzumab to MS patients, Genzyme's ability to develop and obtain approval of a patient safety plan, and the other risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ending June 30, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements.

Genzyme and Campath(R) and MabCampath(R) are registered trademarks of Genzyme Corporation. Rebif(R) is a registered trademark of EMD Serono, Inc.

Genzyme's press releases and other comp
'/>"/>

SOURCE Genzyme Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...
4. Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
5. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
6. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
7. Cobalis Expects to Report Phase III Top-Line Results in May
8. XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512 in Restless Legs Syndrome
9. Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntingtons Disease
10. UCB Announces Positive Top-Line Phase III Results for Keppra as Adjunctive Therapy for Partial Onset Seizures in Paediatric Patients from One Month to Less than Four Years of Age
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... PHILADELPHIA , 22. Mai 2013 /PRNewswire/ ... Sitz in Barcelona , ... aufzeigt, dass eine höhere Dosis von PROLASTIN©-C ... Patienten mit Alpha1-Antitrypsinmangel (AAT) auf ein Niveau ... normal bezeichneten Bereichs liegt. ATT-Mangel ist eine ...
(Date:5/22/2013)... TORONTO , May 22, 2013  Medifocus, ... John Mon , Chief Operating Officer, will present ... May 30, 2013 in New York City ... Company,s presentation is scheduled to begin at 4:00 p.m. EDT ... the webcast, go to:   http://wsw.com/webcast/marcum/mfs.v/   For ...
(Date:5/22/2013)... 2013 Cellular Biomedicine Group (OTCQB: CBMG) today announced ... total projected enrollment required for its Phase I trial to ... Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the ... has had no Severe Adverse Effect (SAE) reported. ... registered with NIH under number NCT01828762 (click here to ...
Breaking Medicine Technology:Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 2Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 3Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer 2Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer 3
... world-leading developer and marketer of innovative medical technologies for community ... $10,000 to the AAWC Global Volunteers program through the SAWC ... 25th Annual Symposium on Advanced Wound Care and Wound Healing ... 22, 2012. The Association for the Advancement ...
... Fla., April 23, 2012  SurgLine International, Inc. (SGLN.PK) ... Inc. ("SGLN") and SurgLine, Inc. ("SurgLine") stated that ... has formed SurgLine MDC Holdings, LLC. ("SMDC"), a ... subsidiary.  SMDC will be forming  joint-venture opportunities with ...
Cached Medicine Technology:ConvaTec Donates $10,000 To AAWC Global Volunteers Program Through SAWC Walk For Wellness 2ConvaTec Donates $10,000 To AAWC Global Volunteers Program Through SAWC Walk For Wellness 3SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies 2
(Date:5/22/2013)... Teams who focus on productivity, process, quality, 5S ... StepTracker whiteboard as a rallying point for project management ... the current status of our company-wide lean initiatives and ... listed down the side and the milestones are along ... are filled with yellow circles. Turning the magnets over ...
(Date:5/22/2013)... 21 May 2013, Paris, France: Results from ... 2013 today question whether bivalirudin is superior ... blockade, showing similar 30-day mortality in patients ... (NSTE-ACS) undergoing percutaneous coronary intervention (PCI)., European ... alone as an alternative to unfractionated heparin ...
(Date:5/22/2013)... PA (PRWEB) May 22, 2013 The ... announce its participation in the Greater Philadelphia Tour de Cure, ... recreational riders who are passionate about stopping the spread ... 25 million Americans. , The Tour de Cure will ... at 580 Meetinghouse Road in Ambler, 30 minutes outside of ...
(Date:5/22/2013)... 22, 2013 According to the latest “ ... ” article published recently at FinancesOnline.com the wailing and flailing ... Centers for Disease Control and Prevention 2012 report points ... are overweight, 35.7% are obese, and 6.3% are extremely obese. ... article. In particular, the article focuses on a sector that ...
(Date:5/22/2013)... 2013 Synthetic Turf International has ... Play & Recreation Contest, who collectively have helped ... youth, people with disabilities, active troops and military ... general public is encouraged to vote online now ... non-profit organization win the $50,000 synthetic turf installation ...
Breaking Medicine News(10 mins):Health News:Project Managers Organize Manufacturing Projects and Training with the New Steptracker Project Status Magnetic Whiteboards 2Health News:Registry questions superiority of bivalirudin over heparin 2Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 2Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 3Health News:Black American Obesity Examined In The Latest FinancesOnline.com Article 2Health News:Black American Obesity Examined In The Latest FinancesOnline.com Article 3Health News:Public Voting Opens for Finalists in Synthetic Turf International’s Better Play & Recreation Contest 2
... News) --,Americans, awareness of chronic obstructive pulmonary disease (COPD) is ... their doctor about symptoms, according to a new survey by ... of COPD -- the third-leading cause of death in the ... wheezing, excess sputum production and a feeling of not being ...
... Randy Dotinga HealthDay Reporter , THURSDAY, Dec. ... physical activity might encourage better shut-eye: People who met ... fatigue than those who didn,t. The research doesn,t ... it,s possible there may be another explanation for the ...
... A diametric shift in the levels of two ... enables accumulation of the destructive brain plaque found in ... that folds others into specific positions to unleash their ... aging, it unleashes the normally dormant BACE1, a protein ...
... discovered that over a million people worldwide diagnosed with TB ... which is usually left untreated because it is mistaken for ... published today in the Bulletin of the World Health ... of Toronto say because the X-ray features and symptoms are ...
... WASHINGTON, Dec. 1, 2011 The American Chemical Society,s (ACS,) ... conferences of the New Year, will be held March ... place at the San Diego Convention Center and at area ... that span science,s horizons from astronomy to zoology ― ...
... that epigallocatechin-3-gallate (EGCG)a flavonoid found in green teainhibits the ... findings available in the December issue of Hepatology ... the American Association for the Study of Liver Diseases, ... prevent HCV reinfection following liver transplantation. HCV ...
Cached Medicine News:Health News:Many Ignore Symptoms of Lung Disease, Study Finds 2Health News:More Exercise Could Make For Better Sleep: Study 2Health News:More Exercise Could Make For Better Sleep: Study 3Health News:Diametric shift in 2 protein levels spurs Alzheimer's plaque accumulation 2Health News:Mistaken identity: New report highlights the global impact of medical misdiagnosis 2Health News:Green tea flavonoid may prevent reinfection with hepatitis C virus following liver transplantation 2
... The new SureCut M3500 Radial Microtome has ... is marvelous, and a range of functions and ... users. Based on years of experience and ... innovative design the SureCut M3500 Microtome will be ...
Clock oil, 6 grams net...
Knife sharpening back for Standard Knife, C Profile...
Knife sharpening kit...
Medicine Products: